|
 |
|
|
|
|
|||||
|
Marshall Edwards, Inc. ('MEI') is a pharmaceutical company dedicated to the field of cancer therapy (oncology). MEI is developing a range of anti-cancer therapies that represents the next generation of oncology drugs - multiple signal transduction regulators (abbreviated as 'MSTR') that reach to the heart of the cancer process. The source of this new range of drugs is a family of chemicals, discovered by pharmaceutical company Novogen, that act against the fundamentals of the cancer process. Using this single technology platform, MEI is developing a number of drugs with novel actions against a range of different cancer types. The first of these drugs - phenoxodiol - has advanced to Phase III clinical studies. Go to Newsroom for the latest announcement and clinical trials for a listing of the current trials. Please note that MEI has announced the cessation of recruitment for the OVATURE trial. See announcement. Go to OVATURE trial if you would like more detail on the OVArian TUmor REsponse (OVATURE) Study. |
140 Wicks Road North Ryde NSW 2113 Australia T: +61 2 8877 6196  |
      
|
| . |
home
: about us.
: about phenoxodiol
: the technology
: newsroom
: Marshall Edwards Inc. 2001 ©
|